{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:39:19Z","timestamp":1792201159935,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bladder cancer (BLCA) is one of the most frequent genitourinary cancers, with a high rate of morbidity and mortality. The connection of m6A-related lncRNAs with PD-L1 and tumor immune microenvironment (TIME) in BLCA prognosis was extensively investigated in this study, which could suggest novel therapeutic targets for further investigation. 30 m6A-associated lncRNAs with predictive values from the TCGA data set were identified with co-expression analysis. Cluster2 was correlated with a poor prognosis, upregulated\u00a0PD-L1 expression, and higher immune ratings. Cluster2 had larger amounts of resting CD4 memory-activated T cells, M2 macrophages, neutrophils, and NK cells infiltration. \u201cCHEMOKINE SIGNALING PATHWAY\u201d was the most significantly enriched signaling pathway according to GSEA, which may play an important role in the different immune cell infiltrates between cluster1\/2. The risk model for m6A-related lncRNAs could be employed in a prognostic model to predict BLCA prognosis, regardless of other clinical features. Collectively, m6A-related lncRNAs were linked to PD-L1 and TIME, which would dynamically affect the number of tumor-infiltrating immune cells. m6A-related lncRNAs may be key mediators of PD-L1 expression and immune cells infiltration and may strongly affect the TIME of BLCA.\n<\/jats:p>","DOI":"10.1038\/s41598-022-14097-x","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T11:04:34Z","timestamp":1655377474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"M. Q.","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. D.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Q.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"1","key":"14097_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni, S. et al. Bladder cancer incidence and mortality: A global overview and recent trends. Eur. Urol. 71(1), 96\u2013108 (2017).","journal-title":"Eur. Urol."},{"issue":"5","key":"14097_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"key":"14097_CR3","first-page":"S03022838163029","volume":"2016","author":"JA Witjes","year":"2016","unstructured":"Witjes, J. A. et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 2016, S0302283816302901 (2016).","journal-title":"Eur. Urol."},{"key":"14097_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive Stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Gu\u00e9rin. Eur. Urol. 69, 60\u201369 (2016).","journal-title":"Eur. Urol."},{"key":"14097_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","volume":"73","author":"B Szabados","year":"2017","unstructured":"Szabados, B. et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. Eur. Urol. 73, 149 (2017).","journal-title":"Eur. Urol."},{"issue":"2","key":"14097_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12013-013-9555-2","volume":"67","author":"H Akhavan-Niaki","year":"2013","unstructured":"Akhavan-Niaki, H. & Samadani, A. A. DNA methylation and cancer development: Molecular mechanism. Cell Biochem. Biophys. 67(2), 501\u2013513 (2013).","journal-title":"Cell Biochem. Biophys."},{"issue":"6","key":"14097_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.tig.2017.04.003","volume":"33","author":"JY Roignant","year":"2017","unstructured":"Roignant, J. Y. & Soller, M. m(6)A in mRNA: An ancient mechanism for fine-tuning gene expression. Trends Genet. 33(6), 380\u2013390 (2017).","journal-title":"Trends Genet."},{"issue":"12","key":"14097_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-020-00736-4","volume":"52","author":"MAJ Morgan","year":"2020","unstructured":"Morgan, M. A. J. & Shilatifard, A. Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation. Nat. Genet. 52(12), 1271\u20131281 (2020).","journal-title":"Nat. Genet."},{"issue":"5539","key":"14097_CR9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1126\/science.1064413","volume":"293","author":"MD Litt","year":"2001","unstructured":"Litt, M. D. et al. Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 293(5539), 2453\u20132455 (2001).","journal-title":"Science"},{"issue":"5532","key":"14097_CR10","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.1064150","volume":"293","author":"K Noma","year":"2001","unstructured":"Noma, K., Allis, C. D. & Grewal, S. I. Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science 293(5532), 1150\u20131155 (2001).","journal-title":"Science"},{"issue":"5","key":"14097_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41556-019-0311-8","volume":"21","author":"RW Yao","year":"2019","unstructured":"Yao, R. W., Wang, Y. & Chen, L. L. Cellular functions of long noncoding RNAs. Nat. Cell Biol. 21(5), 542 (2019).","journal-title":"Nat. Cell Biol."},{"issue":"7","key":"14097_CR12","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/cancers13071587","volume":"13","author":"MT Di Martino","year":"2021","unstructured":"Di Martino, M. T. et al. miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy. Cancers (Basel) 13(7), 1587 (2021).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"14097_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/1878-0261.12413","volume":"13","author":"N Denaro","year":"2019","unstructured":"Denaro, N., Merlano, M. C. & Nigro, C. L. Long noncoding RNAs as regulators of cancer immunity. Mol. Oncol. 13(1), 61 (2019).","journal-title":"Mol. Oncol."},{"key":"14097_CR14","first-page":"61","volume":"13","author":"D Huang","year":"2018","unstructured":"Huang, D. et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat. Immunol. 13, 61 (2018).","journal-title":"Nat. Immunol."},{"key":"14097_CR15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1089\/hum.2018.048","volume":"29","author":"S Zhen","year":"2018","unstructured":"Zhen, S. et al. Synergistic antitumor effect on bladder cancer by rational combination of programmed cell death 1 blockade and CRISPR-Cas9-mediated long non-coding RNA urothelial carcinoma associated 1 knockout. Hum. Gene Therapy 29, 1352 (2018).","journal-title":"Hum. Gene Therapy"},{"key":"14097_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fcell.2019.00116","volume":"7","author":"F Fazi","year":"2019","unstructured":"Fazi, F. & Fatica, A. Interplay between N6-methyladenosine (m6A) and non-coding RNAs in cell development and cancer. Front. Cell Dev. Biol. 7, 116 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"14097_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omtn.2020.08.004","volume":"22","author":"F Dai","year":"2020","unstructured":"Dai, F. et al. Crosstalk between RNA m6A modification and non-coding RNA contributes to cancer growth and progression. Mol. Therapy Nucleic Acids 22, 62 (2020).","journal-title":"Mol. Therapy Nucleic Acids"},{"key":"14097_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.gendis.2020.03.005","volume":"7","author":"RZ He","year":"2020","unstructured":"He, R. Z., Jiang, J. & Luo, D. X. The functions of N6-methyladenosine modification in lncRNAs. Genes Dis. 7, 598 (2020).","journal-title":"Genes Dis."},{"key":"14097_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01233-2","author":"YC Yi","year":"2020","unstructured":"Yi, Y. C. et al. Novel insights into the interplay between m6A modification and noncoding RNAs in cancer. Mol. Cancer. https:\/\/doi.org\/10.1186\/s12943-020-01233-2 (2020).","journal-title":"Mol. Cancer."},{"issue":"3","key":"14097_CR20","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s12035-018-1138-1","volume":"56","author":"K Du","year":"2019","unstructured":"Du, K. et al. m(6)A RNA methylation controls neural development and is involved in human diseases. Mol. Neurobiol. 56(3), 1596\u20131606 (2019).","journal-title":"Mol. Neurobiol."},{"key":"14097_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2017.08.030","volume":"408","author":"S Wang","year":"2017","unstructured":"Wang, S. et al. Roles of RNA methylation by means of N(6)-methyladenosine (m(6)A) in human cancers. Cancer Lett. 408, 112\u2013120 (2017).","journal-title":"Cancer Lett."},{"key":"14097_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.11.007","author":"X Han","year":"2020","unstructured":"Han, X. et al. RNA methylations in human cancers. Semin. Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.007 (2020).","journal-title":"Semin. Cancer Biol."},{"issue":"70","key":"14097_CR23","doi-asserted-by":"publisher","first-page":"33403","DOI":"10.18632\/oncotarget.23607","volume":"9","author":"Y Zhou","year":"2017","unstructured":"Zhou, Y. et al. Cancer stem cells in progression of colorectal cancer. Oncotarget 9(70), 33403 (2017).","journal-title":"Oncotarget"},{"key":"14097_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3389\/fimmu.2018.01578","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Immune landscape of colorectal cancer tumor microenvironment from different primary tumor location. Front. Immunol. 9, 1578 (2018).","journal-title":"Front. Immunol."},{"key":"14097_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hep.28885","volume":"65","author":"J-Z Ma","year":"2017","unstructured":"Ma, J.-Z. et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6-methyladenosine-dependent primary microRNA processing. Hepatology (Baltimore) 65, 529 (2017).","journal-title":"Hepatology (Baltimore)"},{"issue":"4","key":"14097_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/cancers12040771","volume":"12","author":"D Barros-Silva","year":"2020","unstructured":"Barros-Silva, D. et al. VIRMA-dependent N6-methyladenosine modifications regulate the expression of long non-coding RNAs CCAT1 and CCAT2 in prostate cancer. Cancers 12(4), 771 (2020).","journal-title":"Cancers"},{"key":"14097_CR27","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/cam4.2833","volume":"9","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma. Cancer Med. 9, 1877 (2020).","journal-title":"Cancer Med."},{"key":"14097_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.omto.2020.04.011","volume":"17","author":"Z Meng","year":"2020","unstructured":"Meng, Z. et al. The m6A-related mRNA signature predicts the prognosis of pancreatic cancer patients. Mol. Therapy Oncol. 17, 460 (2020).","journal-title":"Mol. Therapy Oncol."},{"key":"14097_CR29","doi-asserted-by":"publisher","first-page":"637933","DOI":"10.3389\/fimmu.2021.637933","volume":"12","author":"Y Jin","year":"2021","unstructured":"Jin, Y. et al. Analysis of m6A-related signatures in the tumor immune microenvironment and identification of clinical prognostic regulators in adrenocortical carcinoma. Front. Immunol. 12, 637933 (2021).","journal-title":"Front. Immunol."},{"issue":"6","key":"14097_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41374-021-00543-3","volume":"101","author":"J Shen","year":"2021","unstructured":"Shen, J. et al. N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma. Lab Investig. 101(6), 775\u2013784 (2021).","journal-title":"Lab Investig."},{"issue":"1","key":"14097_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10120-020-01099-9","volume":"24","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. RP11\u2013323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription. Gastric Cancer 24(1), 85\u2013102 (2021).","journal-title":"Gastric Cancer"},{"issue":"2","key":"14097_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell 175(2), 313\u2013326 (2018).","journal-title":"Cell"},{"issue":"3","key":"14097_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CCO.0000000000000177","volume":"27","author":"JW Kim","year":"2015","unstructured":"Kim, J. W. et al. Emerging immunotherapies for bladder cancer. Curr. Opin. Oncol. 27(3), 191\u2013200 (2015).","journal-title":"Curr. Opin. Oncol."},{"key":"14097_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.omtn.2020.06.001","volume":"21","author":"L Yi","year":"2020","unstructured":"Yi, L. et al. Comprehensive analysis of the PD-L1 and immune infiltrates of m(6)A RNA methylation regulators in head and neck squamous cell carcinoma. Mol. Ther. Nucleic Acids 21, 299\u2013314 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10061","key":"14097_CR35","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388(10061), 2796\u20132810 (2016).","journal-title":"Lancet"},{"issue":"7","key":"14097_CR36","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-18-2965","volume":"79","author":"Q Lan","year":"2019","unstructured":"Lan, Q. et al. The critical role of RNA m(6)A methylation in cancer. Cancer Res. 79(7), 1285\u20131292 (2019).","journal-title":"Cancer Res."},{"issue":"2","key":"14097_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41419-017-0129-x","volume":"9","author":"D Dai","year":"2018","unstructured":"Dai, D. et al. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 9(2), 124 (2018).","journal-title":"Cell Death Dis."},{"issue":"16","key":"14097_CR38","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.18632\/aging.102185","volume":"11","author":"A He","year":"2019","unstructured":"He, A. et al. Prognostic value of long non-coding RNA signatures in bladder cancer. Aging (Albany) 11(16), 6237\u20136251 (2019).","journal-title":"Aging (Albany)"},{"issue":"17","key":"14097_CR39","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.18632\/aging.102225","volume":"11","author":"P Lian","year":"2019","unstructured":"Lian, P. et al. An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer. Aging (Albany) 11(17), 6930\u20136940 (2019).","journal-title":"Aging (Albany)"},{"issue":"10","key":"14097_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41590-018-0207-y","volume":"19","author":"D Huang","year":"2018","unstructured":"Huang, D. et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat. Immunol. 19(10), 1112\u20131125 (2018).","journal-title":"Nat. Immunol."},{"key":"14097_CR41","doi-asserted-by":"publisher","first-page":"106641","DOI":"10.1016\/j.intimp.2020.106641","volume":"85","author":"F Li","year":"2020","unstructured":"Li, F. et al. Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer. Int. Immunopharmacol. 85, 106641 (2020).","journal-title":"Int. Immunopharmacol."},{"issue":"12","key":"14097_CR42","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1089\/hum.2018.048","volume":"29","author":"S Zhen","year":"2018","unstructured":"Zhen, S. et al. Synergistic antitumor effect on bladder cancer by rational combination of programmed cell death 1 blockade and CRISPR-Cas9-mediated long non-coding RNA urothelial carcinoma associated 1 knockout. Hum. Gene Ther. 29(12), 1352\u20131363 (2018).","journal-title":"Hum. Gene Ther."},{"key":"14097_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2018.00049","volume":"8","author":"AR Poh","year":"2018","unstructured":"Poh, A. R. & Ernst, M. Targeting macrophages in cancer: From bench to bedside. Front. Oncol. 8, 49 (2018).","journal-title":"Front. Oncol."},{"issue":"4","key":"14097_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.it.2015.02.004","volume":"36","author":"R Ostuni","year":"2015","unstructured":"Ostuni, R. et al. Macrophages and cancer: From mechanisms to therapeutic implications. Trends Immunol. 36(4), 229\u2013239 (2015).","journal-title":"Trends Immunol."},{"issue":"1","key":"14097_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: From mechanisms to therapy. Immunity 41(1), 49\u201361 (2014).","journal-title":"Immunity"},{"issue":"6","key":"14097_CR46","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140(6), 883\u2013899 (2010).","journal-title":"Cell"},{"issue":"1","key":"14097_CR47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41598-017-00382-7","volume":"7","author":"IH Chung","year":"2017","unstructured":"Chung, I. H. et al. The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma. Sci. Rep. 7(1), 295 (2017).","journal-title":"Sci. Rep."},{"issue":"2","key":"14097_CR48","first-page":"581","volume":"42","author":"Y Xue","year":"2019","unstructured":"Xue, Y. et al. Tumor-infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. Oncol. Rep. 42(2), 581\u2013594 (2019).","journal-title":"Oncol. Rep."},{"issue":"9","key":"14097_CR49","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1158\/0008-5472.CAN-15-2386","volume":"76","author":"I De","year":"2016","unstructured":"De, I. et al. CSF1 overexpression promotes high-grade glioma formation without impacting the polarization status of glioma-associated microglia and macrophages. Cancer Res. 76(9), 2552\u20132560 (2016).","journal-title":"Cancer Res."},{"issue":"9","key":"14097_CR50","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.4049\/jimmunol.181.9.6384","volume":"181","author":"Y Wu","year":"2008","unstructured":"Wu, Y. et al. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J. Immunol. 181(9), 6384\u20136393 (2008).","journal-title":"J. Immunol."},{"issue":"49","key":"14097_CR51","doi-asserted-by":"publisher","first-page":"34342","DOI":"10.1074\/jbc.M109.042671","volume":"284","author":"H Roca","year":"2009","unstructured":"Roca, H. et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 284(49), 34342\u201334354 (2009).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"14097_CR52","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1084\/jem.179.3.881","volume":"179","author":"PJ Jose","year":"1994","unstructured":"Jose, P. J. et al. Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J. Exp. Med. 179(3), 881\u2013887 (1994).","journal-title":"J. Exp. Med."},{"issue":"14","key":"14097_CR53","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.18632\/oncotarget.2110","volume":"5","author":"C Tripathi","year":"2014","unstructured":"Tripathi, C. et al. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 5(14), 5350\u20135368 (2014).","journal-title":"Oncotarget"},{"issue":"11","key":"14097_CR54","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","volume":"97","author":"T Ishida","year":"2006","unstructured":"Ishida, T. & Ueda, R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 97(11), 1139\u20131146 (2006).","journal-title":"Cancer Sci."},{"key":"14097_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J., Powles, T. & Vogelzang, N. J. A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat. Rev. 54, 58\u201367 (2017).","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"14097_CR56","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi, J. et al. Overexpression of B7\u2013H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56(8), 1173\u20131182 (2007).","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"14097_CR57","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman, B. A. et al. PD-L1 (B7\u2013H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer 109(8), 1499\u20131505 (2007).","journal-title":"Cancer"},{"issue":"20","key":"14097_CR58","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1002\/cam4.3400","volume":"9","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Med. 9(20), 7729\u20137741 (2020).","journal-title":"Cancer Med."},{"key":"14097_CR59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-4939-3578-9_6","volume":"1418","author":"Z Wang","year":"2016","unstructured":"Wang, Z., Jensen, M. A. & Zenklusen, J. C. A practical guide to the cancer genome atlas (TCGA). Methods Mol. Biol. 1418, 111\u2013141 (2016).","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"14097_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12(5), 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"14097_CR61","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14097-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:48:59Z","timestamp":1669355339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14097-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14097"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14097-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10082"}}